Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  The adequacy of product liability insurance to defend against lawsuits;  Increases in product liability insurance coverage costs, retention, and claims years covered;  The outcome of lawsuits filed against the Company, and of the SEC investigation;  The impact of the FDA Order and subsequent FDA activity, including the FDAs letters regarding the SynerGraft process and measures taken by the Company as a result, on future revenues, profits, and business operations;  The impact of the FDAs Form 483 Notices of Observation;  The Companys estimated future liability for existing product liability lawsuits and for product liability claims incurred but not yet reported;  The Companys ability to increase yields and reduce its costs of tissue preservation services;  The Companys competitive position, including the impact of price increases;  The receipt of governmental grants for BioFoam development;  The results of patient studies and their use in applying for governmental approval for products and services;  The outcome of the Companys regulatory applications regarding its SynerGraft process; 34  Future increases in research and development expenses;  Competitive advantages offered by the Companys patents, trade secrets, trademarks, and technology licensing rights;  Product demand and market growth;  The success of the RTI Agreement, including anticipated cost savings and increased procurement of cardiovascular and vascular tissues;  The potential of the ACT for use in fibrinolysis (blood clot dissolving) and other drug delivery applications;  Expected revenue and earnings growth from recently announced strategic agreements;  Expected impact of adoption of new accounting pronouncements;  The impact on the Company of adverse publicity or negative surgical outcomes from products or services provided by the Company;  Anticipated future revenues and expenses;  Expected seasonality trends;  Anticipated decreases in cash payments related to the defense and resolution of lawsuits and claims from the levels seen in 2003 through 2006;  Anticipated impact of changes in interest rates;  The ability to expand the Companys service and product offerings;  The success of distribution, supplier and development agreements with third parties to distribute, supply and develop various Company, as well as third party, products and services;  Those issues most likely to impact the Companys future financial performance and cash flows;  The Companys ability to implement its strategic plans;  The adequacy of the Companys financial resources and its ability to borrow under its credit facility; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including the risk factors discussed in this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 35 Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the Securities and Exchange Commission regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2006 (the end of the fiscal year to which this Form 10-K relates). 